Figures & data
Figure 1 miR-495 was downregulated in melanoma tissues and cell lines. (A) qPCR analysis of miR-495 expression in 15 paired melanoma tissues and adjacent normal tissues. (B) qPCR analysis of miR-495 expression in primary human epidermal melanocytes (PEM) and various melanoma cell lines (A7, WM-115, MeWo, SK-MEL-28, A375). Data are presented as mean ± SD (n=3). Each experiment was performed in triplicate. *P<0.05, ***P<0.001.
![Figure 1 miR-495 was downregulated in melanoma tissues and cell lines. (A) qPCR analysis of miR-495 expression in 15 paired melanoma tissues and adjacent normal tissues. (B) qPCR analysis of miR-495 expression in primary human epidermal melanocytes (PEM) and various melanoma cell lines (A7, WM-115, MeWo, SK-MEL-28, A375). Data are presented as mean ± SD (n=3). Each experiment was performed in triplicate. *P<0.05, ***P<0.001.](/cms/asset/e95123a0-f35d-429b-9658-2129be9b9ae1/dott_a_152362_f0001_b.jpg)
Figure 2 miR-495 inhibits melanoma cell proliferation, migration, invasion, and colony formation in vitro. (A) A375 and MeWo cells were transfected with miR-495 mimics, negative control (miR-NC), negative control inhibitor (NC inhibitor), or miR-495 inhibitor for 24 hours, then the expression of miR-495 was quantified by qRT-PCR. (B) miR-495 mimics, miR-NC, NC inhibitor or miR-495 inhibitor-transfected A375, and MeWo cells were subjected to MTT assay. (C) miR-495 mimics, miR-NC, NC inhibitor or miR-495 inhibitor-transfected A375, and MeWo cells were subjected to wound healing assay. (D) miR-495 mimics, miR-NC, NC inhibitor or miR-495 inhibitor-transfected A375, and MeWo cells were subjected to transwell assay. (E) miR-495 mimics, miR-NC, NC inhibitor or miR-495 inhibitor-transfected A375, and MeWo cells were subjected to colony formation assay. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. *P<0.05, **P<0.01, ***P<0.001.
![Figure 2 miR-495 inhibits melanoma cell proliferation, migration, invasion, and colony formation in vitro. (A) A375 and MeWo cells were transfected with miR-495 mimics, negative control (miR-NC), negative control inhibitor (NC inhibitor), or miR-495 inhibitor for 24 hours, then the expression of miR-495 was quantified by qRT-PCR. (B) miR-495 mimics, miR-NC, NC inhibitor or miR-495 inhibitor-transfected A375, and MeWo cells were subjected to MTT assay. (C) miR-495 mimics, miR-NC, NC inhibitor or miR-495 inhibitor-transfected A375, and MeWo cells were subjected to wound healing assay. (D) miR-495 mimics, miR-NC, NC inhibitor or miR-495 inhibitor-transfected A375, and MeWo cells were subjected to transwell assay. (E) miR-495 mimics, miR-NC, NC inhibitor or miR-495 inhibitor-transfected A375, and MeWo cells were subjected to colony formation assay. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. *P<0.05, **P<0.01, ***P<0.001.](/cms/asset/48726b1a-62a0-4ae2-8e3c-772f047b3ec0/dott_a_152362_f0002_c.jpg)
Figure 3 Overexpression of miR-495 promotes apoptosis in melanoma cells. A375 and MeWo cells were transfected with miR-NC or miR-495 mimics for 24 cells. (A) Apoptosis rates were analyzed. (B) Caspase-3 activity was analyzed. (C) Total proteins were subjected to Western blot analysis with indicated antibodies. (D) Western blot results were quantitatively analyzed. Data are presented as the mean ± SD (n=3). All experiments were performed three times, and representative images are presented. **P<0.01, ***P<0.001.
![Figure 3 Overexpression of miR-495 promotes apoptosis in melanoma cells. A375 and MeWo cells were transfected with miR-NC or miR-495 mimics for 24 cells. (A) Apoptosis rates were analyzed. (B) Caspase-3 activity was analyzed. (C) Total proteins were subjected to Western blot analysis with indicated antibodies. (D) Western blot results were quantitatively analyzed. Data are presented as the mean ± SD (n=3). All experiments were performed three times, and representative images are presented. **P<0.01, ***P<0.001.](/cms/asset/344ecf9e-1608-4b37-9e75-2d6b04f1e87b/dott_a_152362_f0003_b.jpg)
![Figure 3 Overexpression of miR-495 promotes apoptosis in melanoma cells. A375 and MeWo cells were transfected with miR-NC or miR-495 mimics for 24 cells. (A) Apoptosis rates were analyzed. (B) Caspase-3 activity was analyzed. (C) Total proteins were subjected to Western blot analysis with indicated antibodies. (D) Western blot results were quantitatively analyzed. Data are presented as the mean ± SD (n=3). All experiments were performed three times, and representative images are presented. **P<0.01, ***P<0.001.](/cms/asset/04988441-bfa9-4253-88b2-8bf4ccfe0a23/dott_a_152362_f0003a_b.jpg)
Figure 4 Pre-B-cell leukemia transcription factor 3 (PBX3) is a direct target of miR-495 in melanoma cells. (A) Human PBX3 3′UTR binding site for miR-495. (B) miR-495 targeted the wild-type but not the mutant 3′UTR of PBX3. (C) Overexpression of miR-495 repressed PBX3 mRNA expression level (left) and protein level (middle and right) in A375 and MeWo cells. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. **P<0.01.
![Figure 4 Pre-B-cell leukemia transcription factor 3 (PBX3) is a direct target of miR-495 in melanoma cells. (A) Human PBX3 3′UTR binding site for miR-495. (B) miR-495 targeted the wild-type but not the mutant 3′UTR of PBX3. (C) Overexpression of miR-495 repressed PBX3 mRNA expression level (left) and protein level (middle and right) in A375 and MeWo cells. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. **P<0.01.](/cms/asset/7e6985af-ad35-4838-a177-5ee0bb514bbb/dott_a_152362_f0004_b.jpg)
Figure 5 Silencing of pre-B-cell leukemia transcription factor 3 (PBX3)-inhibited cell proliferation, migration, and invasion in melanoma cells. (A) A375 and MeWo cells were transfected with negative control siRNA (si-NC) or siRNA against PBX3 (si-PBX3) for 24 hours, the mRNA expression levels of PBX3 in both the cells were examined by RT-qPCR and (B) the protein levels of PBX3 in both the cells were examined by Western blot. (C) A375 and MeWo cells were transfected with si-NC or si-PBX3 for indicated time, and cell proliferation was analyzed by MTT assay. (D) A375 and MeWo cells were transfected with si-NC or by transwell assay. (E) Cell migration was analyzed by si-PBX3 for 24 hours, and cell invasion was analyzed by wound healing assay. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. *P<0.05, **P<0.01, ***P<0.001.
![Figure 5 Silencing of pre-B-cell leukemia transcription factor 3 (PBX3)-inhibited cell proliferation, migration, and invasion in melanoma cells. (A) A375 and MeWo cells were transfected with negative control siRNA (si-NC) or siRNA against PBX3 (si-PBX3) for 24 hours, the mRNA expression levels of PBX3 in both the cells were examined by RT-qPCR and (B) the protein levels of PBX3 in both the cells were examined by Western blot. (C) A375 and MeWo cells were transfected with si-NC or si-PBX3 for indicated time, and cell proliferation was analyzed by MTT assay. (D) A375 and MeWo cells were transfected with si-NC or by transwell assay. (E) Cell migration was analyzed by si-PBX3 for 24 hours, and cell invasion was analyzed by wound healing assay. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. *P<0.05, **P<0.01, ***P<0.001.](/cms/asset/319125c7-a639-480a-be9f-2c2667c2ae97/dott_a_152362_f0005_b.jpg)
![Figure 5 Silencing of pre-B-cell leukemia transcription factor 3 (PBX3)-inhibited cell proliferation, migration, and invasion in melanoma cells. (A) A375 and MeWo cells were transfected with negative control siRNA (si-NC) or siRNA against PBX3 (si-PBX3) for 24 hours, the mRNA expression levels of PBX3 in both the cells were examined by RT-qPCR and (B) the protein levels of PBX3 in both the cells were examined by Western blot. (C) A375 and MeWo cells were transfected with si-NC or si-PBX3 for indicated time, and cell proliferation was analyzed by MTT assay. (D) A375 and MeWo cells were transfected with si-NC or by transwell assay. (E) Cell migration was analyzed by si-PBX3 for 24 hours, and cell invasion was analyzed by wound healing assay. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. *P<0.05, **P<0.01, ***P<0.001.](/cms/asset/7c136341-1fa1-497c-99fa-d3e39d8c56a5/dott_a_152362_f0005a_c.jpg)
Figure 6 Knockdown of pre-B-cell leukemia transcription factor 3 (PBX3) promotes apoptosis in melanoma cells. Melanoma A375 and MeWo cells were transfected with negative control siRNA (si-NC) or siRNA against PBX3 (si-PBX3) for 24 hours. (A) Cell apoptosis rates were analyzed. (B) Caspase-3 activity was analyzed. (C) Total lysates were subjected to Western blot analysis with the indicated antibodies. (D) Western blot results were quantitatively analyzed. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. **P<0.01, ***P<0.001.
![Figure 6 Knockdown of pre-B-cell leukemia transcription factor 3 (PBX3) promotes apoptosis in melanoma cells. Melanoma A375 and MeWo cells were transfected with negative control siRNA (si-NC) or siRNA against PBX3 (si-PBX3) for 24 hours. (A) Cell apoptosis rates were analyzed. (B) Caspase-3 activity was analyzed. (C) Total lysates were subjected to Western blot analysis with the indicated antibodies. (D) Western blot results were quantitatively analyzed. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. **P<0.01, ***P<0.001.](/cms/asset/328d380f-6ab6-47e1-9e27-68ec3a64becd/dott_a_152362_f0006_b.jpg)
![Figure 6 Knockdown of pre-B-cell leukemia transcription factor 3 (PBX3) promotes apoptosis in melanoma cells. Melanoma A375 and MeWo cells were transfected with negative control siRNA (si-NC) or siRNA against PBX3 (si-PBX3) for 24 hours. (A) Cell apoptosis rates were analyzed. (B) Caspase-3 activity was analyzed. (C) Total lysates were subjected to Western blot analysis with the indicated antibodies. (D) Western blot results were quantitatively analyzed. Data are presented as mean ± SD (n=3). All experiments were performed three times, and representative images are presented. **P<0.01, ***P<0.001.](/cms/asset/5eec8567-07f4-4bb7-8980-9bcf10838ff1/dott_a_152362_f0006a_b.jpg)